NEW YORK — Martin Shkreli, accused of defrauding his hedge fund investors and a pharmaceutical company, was convicted on three of eight counts on Friday, after a five-week trial in U.S. District Court in Brooklyn, N.Y.Shkreli was accused of securities and wire fraud related to two hedge funds he ran, MSMB Capital and MSMB Healthcare.The prosecution brought forth an “avalanche” of evidence, as prosecutor Jacquelyn Kasulis put it in her rebuttal argument, that included a threatening letter he sent to the wife of a former employee, statements he sent to MSMB investors showing great returns at the same time he had no money in fund accounts, three versions of a backdated agreement to make it look as if MSMB Capital had invested in Retrophin when it had not, as well as claims about assets under management that were wildly out of line with his actual fund size.
NYS Entity Status
NYS Filing Date
SEPTEMBER 25, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN LIMITED PARTNERSHIP
2013 - DELOS INVESTMENT FUND, LP
Around the Web
- Martin Shkreli is found guilty of fraud
By Stephanie Clifford and Colin Moynihan - Friday Aug 4, 2017
- Slack valued at more than $5B after Softbank investment
By Reuters - Monday Sep 18, 2017
Software startup Slack Technologies said it raised $250 million from SoftBank Group and other investors in its latest funding round, boosting the company’s valuation to $5.1 billion. The latest fund-raising, led by SoftBank through its giant Vision Fund and joined by Accel and other investors, lifted Slack’s total funds raised to $841 million, the enterprise...
- Greater Minnesota Housing Fund Launches Impact Investment Fund
By firstname.lastname@example.org (Matt Sinclair) - Thursday Jun 8, 2017
A public-private partnership, the new fund will support efforts to acquire and preserve affordable housing in the Twin Cities....
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Why Nelson Peltz Wants P.&G. to See Him as a ‘Constructivist’
By ANDREW ROSS SORKIN - Tuesday Jul 18, 2017
The financier, who dislikes the term “activist,” has made his name by investing in companies using a friendlier approach. But he’s still an activist.
- Mutual funds slash value of their Uber stakes
By Reuters - Wednesday Aug 23, 2017
Four mutual fund companies have marked down their investments in Uber by as much as 15 percent following a scandal-ridden year for the ride-hailing company. Uber has suffered a series of setbacks in recent months, including a federal probe into its use of technology to evade regulators in certain cities and a trade secrets lawsuit...